Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gin Hwa BiotechROCO:7806 22 Return-on-Tangible-Equity is 8.76% as of Dec. 2025, which is 56% below its 10-year median of 20.03. GuruFocus rates ROCO:7806 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, Gin Hwa Biotech ranks better than 88.41% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Gin Hwa Biotech's annualized net income for the quarter that ended in Dec. 2025 was NT$54.8 Mil. Gin Hwa Biotech's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$626.2 Mil. Therefore, Gin Hwa Biotech's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 8.76%.
The historical rank and industry rank for Gin Hwa Biotech's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:7806'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 12.26 Med: 20.03 Max: 42.37
Current: 13.17
During the past 4 years, Gin Hwa Biotech's highest Return-on-Tangible-Equity was 42.37%. The lowest was 12.26%. And the median was 20.03%.
ROCO:7806's Return-on-Tangible-Equity is ranked better than 88.41% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs ROCO:7806: 13.17
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Gin Hwa Biotech Return-on-Tangible-Equity Related Terms
Gin Hwa Biotech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Gin Hwa Biotech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7806 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Gin Hwa Biotech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gin Hwa Biotech Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gin Hwa Biotech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Gin Hwa Biotech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 8.76% mean?
Gin Hwa Biotech (ROCO:7806) has a Return-on-Tangible-Equity of 8.76% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gin Hwa Biotech and its competitors. This is 56% below median its historical median of 20.03. Over the past decade, Gin Hwa Biotech's Return-on-Tangible-Equity has ranged from 12.26 to 42.37. According to the industry distribution chart, Gin Hwa Biotech ranks #139 out of 1199 companies in the Biotechnology industry, placing it in the top 11.6%.
Is Gin Hwa Biotech's Return-on-Tangible-Equity too high?
Gin Hwa Biotech's current Return-on-Tangible-Equity of 8.76% is 56% below median its 10-year median of 20.03. Over the past 10 years, this metric has ranged from a low of 12.26 to a high of 42.37. Based on the distribution chart, Gin Hwa Biotech ranks #139 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gin Hwa Biotech has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Gin Hwa Biotech's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gin Hwa Biotech ranks #139 out of 1199 companies for Return-on-Tangible-Equity. This places Gin Hwa Biotech in the top 12% of its industry — outperforming the majority of peers. Historically, Gin Hwa Biotech's own Return-on-Tangible-Equity has ranged from 12.26 to 42.37 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gin Hwa Biotech and its competitors. Gin Hwa Biotech's current Return-on-Tangible-Equity is 8.76%, which is 56% below median its own 10-year median of 20.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gin Hwa Biotech stock overvalued right now?
Gin Hwa Biotech (ROCO:7806) has a current Return-on-Tangible-Equity of 8.76%. The current Return-on-Tangible-Equity is 8.76%, which is 56% below median its 10-year median of 20.03. Gin Hwa Biotech's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Gin Hwa Biotech (ROCO:7806), the current Return-on-Tangible-Equity is 8.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gin Hwa Biotech Inc is engaged in developing completely original products to achieve every vision. Its Services and technology are Product Development, OEM Service, Core Technology, R & D Center, Professional Production, and Others.
22GF Score
Get the complete analysis for ROCO:7806
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7806 has been successfully added to your 
